ID   SIR1_HUMAN              Reviewed;         747 AA.
AC   Q96EB6; Q2XNF6; Q5JVQ0; Q9GZR9; Q9Y6F0;
DT   31-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2003, sequence version 2.
DT   12-APR-2017, entry version 166.
DE   RecName: Full=NAD-dependent protein deacetylase sirtuin-1;
DE            Short=hSIRT1;
DE            EC=3.5.1.-;
DE   AltName: Full=Regulatory protein SIR2 homolog 1;
DE   AltName: Full=SIR2-like protein 1;
DE            Short=hSIR2;
DE   Contains:
DE     RecName: Full=SirtT1 75 kDa fragment;
DE              Short=75SirT1;
GN   Name=SIRT1; Synonyms=SIR2L1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=10381378; DOI=10.1006/bbrc.1999.0897;
RA   Frye R.A.;
RT   "Characterization of five human cDNAs with homology to the yeast SIR2
RT   gene: Sir2-like proteins (sirtuins) metabolize NAD and may have
RT   protein ADP-ribosyltransferase activity.";
RL   Biochem. Biophys. Res. Commun. 260:273-279(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH HES1 AND HEY2, AND
RP   MUTAGENESIS OF HIS-363.
RX   PubMed=12535671; DOI=10.1016/S0006-291X(02)03020-6;
RA   Takata T., Ishikawa F.;
RT   "Human Sir2-related protein SIRT1 associates with the bHLH repressors
RT   HES1 and HEY2 and is involved in HES1- and HEY2-mediated
RT   transcriptional repression.";
RL   Biochem. Biophys. Res. Commun. 301:250-257(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLU-3.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 124-747.
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION IN DEACETYLATION OF TP53, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF HIS-363.
RX   PubMed=11672523; DOI=10.1016/S0092-8674(01)00527-X;
RA   Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A.,
RA   Pandita T.K., Guarente L., Weinberg R.A.;
RT   "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.";
RL   Cell 107:149-159(2001).
RN   [7]
RP   FUNCTION, ENZYME ACTIVITY, SUBCELLULAR LOCATION, INTERACTION WITH PML,
RP   AND MUTAGENESIS OF HIS-363.
RX   PubMed=12006491; DOI=10.1093/emboj/21.10.2383;
RA   Langley E., Pearson M., Faretta M., Bauer U.-M., Frye R.A.,
RA   Minucci S., Pelicci P.G., Kouzarides T.;
RT   "Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular
RT   senescence.";
RL   EMBO J. 21:2383-2396(2002).
RN   [8]
RP   ENZYME REGULATION.
RX   PubMed=12297502; DOI=10.1074/jbc.M205670200;
RA   Bitterman K.J., Anderson R.M., Cohen H.Y., Latorre-Esteves M.,
RA   Sinclair D.A.;
RT   "Inhibition of silencing and accelerated aging by nicotinamide, a
RT   putative negative regulator of yeast sir2 and human SIRT1.";
RL   J. Biol. Chem. 277:45099-45107(2002).
RN   [9]
RP   ENZYME REGULATION.
RX   PubMed=12939617; DOI=10.1038/nature01960;
RA   Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S.,
RA   Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.-L.,
RA   Scherer B., Sinclair D.A.;
RT   "Small molecule activators of sirtuins extend Saccharomyces cerevisiae
RT   lifespan.";
RL   Nature 425:191-196(2003).
RN   [10]
RP   FUNCTION.
RX   PubMed=15152190; DOI=10.1038/sj.emboj.7600244;
RA   Frye R.A., Mayo M.W.;
RT   "Modulation of NF-kappaB-dependent transcription and cell survival by
RT   the SIRT1 deacetylase.";
RL   EMBO J. 23:2369-2380(2004).
RN   [11]
RP   FUNCTION IN DEACETYLATION OF FOXO3, AND FUNCTION IN REGULATION OF
RP   FOXO3.
RX   PubMed=14980222; DOI=10.1016/S0092-8674(04)00126-6;
RA   Motta M.C., Divecha N., Lemieux M., Kamel C., Chen D., Gu W.,
RA   Bultsma Y., McBurney M., Guarente L.;
RT   "Mammalian SIRT1 represses forkhead transcription factors.";
RL   Cell 116:551-563(2004).
RN   [12]
RP   FUNCTION IN DEACETYLATION OF MLLT7.
RX   PubMed=15126506; DOI=10.1074/jbc.M401138200;
RA   van der Horst A., Tertoolen L.G.J., de Vries-Smits L.M.M., Frye R.A.,
RA   Medema R.H., Burgering B.M.T.;
RT   "FOXO4 is acetylated upon peroxide stress and deacetylated by the
RT   longevity protein hSir2(SIRT1).";
RL   J. Biol. Chem. 279:28873-28879(2004).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15469825; DOI=10.1016/j.molcel.2004.08.031;
RA   Vaquero A., Scher M., Lee D., Erdjument-Bromage H., Tempst P.,
RA   Reinberg D.;
RT   "Human SirT1 interacts with histone H1 and promotes formation of
RT   facultative heterochromatin.";
RL   Mol. Cell 16:93-105(2004).
RN   [14]
RP   FUNCTION IN DEACETYLATION OF FOXO3, AND FUNCTION IN REGULATION OF
RP   FOXO3.
RX   PubMed=14976264; DOI=10.1126/science.1094637;
RA   Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y.,
RA   Tran H., Ross S.E., Mostoslavsky R., Cohen H.Y., Hu L.S., Cheng H.L.,
RA   Jedrychowski M.P., Gygi S.P., Sinclair D.A., Alt F.W., Greenberg M.E.;
RT   "Stress-dependent regulation of FOXO transcription factors by the
RT   SIRT1 deacetylase.";
RL   Science 303:2011-2015(2004).
RN   [15]
RP   FUNCTION IN DEACETYLATION OF XRCC6, AND INDUCTION BY CR.
RX   PubMed=15205477; DOI=10.1126/science.1099196;
RA   Cohen H.Y., Miller C., Bitterman K.J., Wall N.R., Hekking B.,
RA   Kessler B., Howitz K.T., Gorospe M., de Cabo R., Sinclair D.A.;
RT   "Calorie restriction promotes mammalian cell survival by inducing the
RT   SIRT1 deacetylase.";
RL   Science 305:390-392(2004).
RN   [16]
RP   INTERACTION WITH FHL2, FUNCTION IN DEACETYLATION OF FOXO1, AND
RP   FUNCTION IN REGULATION OF FOXO1.
RX   PubMed=15692560; DOI=10.1038/sj.emboj.7600570;
RA   Yang Y., Hou H., Haller E.M., Nicosia S.V., Bai W.;
RT   "Suppression of FOXO1 activity by FHL2 through SIRT1-mediated
RT   deacetylation.";
RL   EMBO J. 24:1021-1032(2005).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16079181; DOI=10.1091/mbc.E05-01-0033;
RA   Michishita E., Park J.Y., Burneskis J.M., Barrett J.C., Horikawa I.;
RT   "Evolutionarily conserved and nonconserved cellular localizations and
RT   functions of human SIRT proteins.";
RL   Mol. Biol. Cell 16:4623-4635(2005).
RN   [18]
RP   FUNCTION IN DEACETYLATION OF MEF2D, AND INTERACTION WITH HDAC4.
RX   PubMed=16166628; DOI=10.1128/MCB.25.19.8456-8464.2005;
RA   Zhao X., Sternsdorf T., Bolger T.A., Evans R.M., Yao T.-P.;
RT   "Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-
RT   mediated lysine modifications.";
RL   Mol. Cell. Biol. 25:8456-8464(2005).
RN   [19]
RP   INTERACTION WITH HIV-1 TAT.
RX   PubMed=15719057; DOI=10.1371/journal.pbio.0030041;
RA   Pagans S., Pedal A., North B.J., Kaehlcke K., Marshall B.L., Dorr A.,
RA   Hetzer-Egger C., Henklein P., Frye R., McBurney M.W., Hruby H.,
RA   Jung M., Verdin E., Ott M.;
RT   "SIRT1 regulates HIV transcription via Tat deacetylation.";
RL   PLoS Biol. 3:210-220(2005).
RN   [20]
RP   ASSOCIATION WITH THE PRC4 COMPLEX, AND INTERACTION WITH SUZ12.
RX   PubMed=15684044; DOI=10.1073/pnas.0409875102;
RA   Kuzmichev A., Margueron R., Vaquero A., Preissner T.S., Scher M.,
RA   Kirmizis A., Ouyang X., Brockdorff N., Abate-Shen C., Farnham P.J.,
RA   Reinberg D.;
RT   "Composition and histone substrates of polycomb repressive group
RT   complexes change during cellular differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1859-1864(2005).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH E2F1.
RX   PubMed=16892051; DOI=10.1038/ncb1468;
RA   Wang C., Chen L., Hou X., Li Z., Kabra N., Ma Y., Nemoto S.,
RA   Finkel T., Gu W., Cress W.D., Chen J.;
RT   "Interactions between E2F1 and SirT1 regulate apoptotic response to
RT   DNA damage.";
RL   Nat. Cell Biol. 8:1025-1031(2006).
RN   [23]
RP   FUNCTION IN DEACETYLATION OF RB1.
RX   PubMed=17620057; DOI=10.1042/BJ20070151;
RA   Wong S., Weber J.D.;
RT   "Deacetylation of the retinoblastoma tumour suppressor protein by
RT   SIRT1.";
RL   Biochem. J. 407:451-460(2007).
RN   [24]
RP   INTERACTION WITH TLE1.
RX   PubMed=17680780; DOI=10.1042/BJ20070817;
RA   Ghosh H.S., Spencer J.V., Ng B., McBurney M.W., Robbins P.D.;
RT   "Sirt1 interacts with transducin-like enhancer of split-1 to inhibit
RT   nuclear factor kappaB-mediated transcription.";
RL   Biochem. J. 408:105-111(2007).
RN   [25]
RP   FUNCTION, AND MUTAGENESIS OF HIS-363.
RX   PubMed=17290224; DOI=10.1038/sj.emboj.7601563;
RA   Pedersen T.A., Bereshchenko O., Garcia-Silva S., Ermakova O., Kurz E.,
RA   Mandrup S., Porse B.T., Nerlov C.;
RT   "Distinct C/EBPalpha motifs regulate lipogenic and gluconeogenic gene
RT   expression in vivo.";
RL   EMBO J. 26:1081-1093(2007).
RN   [26]
RP   FUNCTION IN DEACETYLATION OF XRCC6, AND FUNCTION IN DNA REPAIR.
RX   PubMed=17334224; DOI=10.1038/emm.2007.2;
RA   Jeong J., Juhn K., Lee H., Kim S.H., Min B.H., Lee K.M., Cho M.H.,
RA   Park G.H., Lee K.H.;
RT   "SIRT1 promotes DNA repair activity and deacetylation of Ku70.";
RL   Exp. Mol. Med. 39:8-13(2007).
RN   [27]
RP   FUNCTION IN DEACETYLATION OF TP73, AND FUNCTION IN REGULATION OF TP73.
RX   PubMed=16998810; DOI=10.1002/jcp.20831;
RA   Dai J.M., Wang Z.Y., Sun D.C., Lin R.X., Wang S.Q.;
RT   "SIRT1 interacts with p73 and suppresses p73-dependent transcriptional
RT   activity.";
RL   J. Cell. Physiol. 210:161-166(2007).
RN   [28]
RP   FUNCTION IN AR-DEPENDENT REPRESSION.
RX   PubMed=17505061; DOI=10.1210/me.2006-0467;
RA   Dai Y., Ngo D., Forman L.W., Qin D.C., Jacob J., Faller D.V.;
RT   "Sirtuin 1 is required for antagonist-induced transcriptional
RT   repression of androgen-responsive genes by the androgen receptor.";
RL   Mol. Endocrinol. 21:1807-1821(2007).
RN   [29]
RP   INTERACTION WITH RPS19BP1.
RX   PubMed=17964266; DOI=10.1016/j.molcel.2007.08.030;
RA   Kim E.-J., Kho J.-H., Kang M.-R., Um S.-J.;
RT   "Active regulator of SIRT1 cooperates with SIRT1 and facilitates
RT   suppression of p53 activity.";
RL   Mol. Cell 28:277-290(2007).
RN   [30]
RP   ERRATUM.
RA   Kim E.-J., Kho J.-H., Kang M.-R., Um S.-J.;
RL   Mol. Cell 28:513-513(2007).
RN   [31]
RP   FUNCTION IN DEACETYLATION OF NR1H3 AND NR1H2.
RX   PubMed=17936707; DOI=10.1016/j.molcel.2007.07.032;
RA   Li X., Zhang S., Blander G., Tse J.G., Krieger M., Guarente L.;
RT   "SIRT1 deacetylates and positively regulates the nuclear receptor
RT   LXR.";
RL   Mol. Cell 28:91-106(2007).
RN   [32]
RP   FUNCTION IN DEACETYLATION OF NBN, AND FUNCTION IN DNA REPAIR.
RX   PubMed=17612497; DOI=10.1016/j.molcel.2007.05.029;
RA   Yuan Z., Zhang X., Sengupta N., Lane W.S., Seto E.;
RT   "SIRT1 regulates the function of the Nijmegen breakage syndrome
RT   protein.";
RL   Mol. Cell 27:149-162(2007).
RN   [33]
RP   FUNCTION IN DEACETYLATION OF HIC1.
RX   PubMed=17283066; DOI=10.1128/MCB.01098-06;
RA   Stankovic-Valentin N., Deltour S., Seeler J., Pinte S., Vergoten G.,
RA   Guerardel C., Dejean A., Leprince D.;
RT   "An acetylation/deacetylation-SUMOylation switch through a
RT   phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1
RT   regulates transcriptional repression activity.";
RL   Mol. Cell. Biol. 27:2661-2675(2007).
RN   [34]
RP   MUTAGENESIS OF HIS-363.
RX   PubMed=18004385; DOI=10.1038/nature06268;
RA   Vaquero A., Scher M., Erdjument-Bromage H., Tempst P., Serrano L.,
RA   Reinberg D.;
RT   "SIRT1 regulates the histone methyl-transferase SUV39H1 during
RT   heterochromatin formation.";
RL   Nature 450:440-444(2007).
RN   [35]
RP   FUNCTION.
RX   PubMed=18662546; DOI=10.1016/j.cell.2008.06.050;
RA   Asher G., Gatfield D., Stratmann M., Reinke H., Dibner C., Kreppel F.,
RA   Mostoslavsky R., Alt F.W., Schibler U.;
RT   "SIRT1 regulates circadian clock gene expression through PER2
RT   deacetylation.";
RL   Cell 134:317-328(2008).
RN   [36]
RP   IDENTIFICATION IN THE ENOSC COMPLEX, FUNCTION, AND MUTAGENESIS OF
RP   HIS-363.
RX   PubMed=18485871; DOI=10.1016/j.cell.2008.03.030;
RA   Murayama A., Ohmori K., Fujimura A., Minami H., Yasuzawa-Tanaka K.,
RA   Kuroda T., Oie S., Daitoku H., Okuwaki M., Nagata K., Fukamizu A.,
RA   Kimura K., Shimizu T., Yanagisawa J.;
RT   "Epigenetic control of rDNA loci in response to intracellular energy
RT   status.";
RL   Cell 133:627-639(2008).
RN   [37]
RP   PHOSPHORYLATION AT SER-27 AND SER-47.
RX   PubMed=18838864; DOI=10.4161/cc.7.19.6799;
RA   Ford J., Ahmed S., Allison S., Jiang M., Milner J.;
RT   "JNK2-dependent regulation of SIRT1 protein stability.";
RL   Cell Cycle 7:3091-3097(2008).
RN   [38]
RP   INTERACTION WITH HIV-1 TAT, AND FUNCTION IN T-CELL ACTIVATION
RP   (MICROBIAL INFECTION).
RX   PubMed=18329615; DOI=10.1016/j.chom.2008.02.002;
RA   Kwon H.S., Brent M.M., Getachew R., Jayakumar P., Chen L.F.,
RA   Schnolzer M., McBurney M.W., Marmorstein R., Greene W.C., Ott M.;
RT   "Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1
RT   deacetylase and induces T cell hyperactivation.";
RL   Cell Host Microbe 3:158-167(2008).
RN   [39]
RP   FUNCTION IN DEACETYLATION OF WRN, AND FUNCTION IN DNA DAMAGE.
RX   PubMed=18203716; DOI=10.1074/jbc.M709707200;
RA   Li K., Casta A., Wang R., Lozada E., Fan W., Kane S., Ge Q., Gu W.,
RA   Orren D., Luo J.;
RT   "Regulation of WRN protein cellular localization and enzymatic
RT   activities by SIRT1-mediated deacetylation.";
RL   J. Biol. Chem. 283:7590-7598(2008).
RN   [40]
RP   FUNCTION IN DEACETYLATION OF STK11.
RX   PubMed=18687677; DOI=10.1074/jbc.M805711200;
RA   Lan F., Cacicedo J.M., Ruderman N., Ido Y.;
RT   "SIRT1 modulation of the acetylation status, cytosolic localization,
RT   and activity of LKB1. Possible role in AMP-activated protein kinase
RT   activation.";
RL   J. Biol. Chem. 283:27628-27635(2008).
RN   [41]
RP   INTERACTION WITH CCAR2, ENZYME REGULATION, MUTAGENESIS OF HIS-363, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18235501; DOI=10.1038/nature06500;
RA   Kim J.-E., Chen J., Lou Z.;
RT   "DBC1 is a negative regulator of SIRT1.";
RL   Nature 451:583-586(2008).
RN   [42]
RP   INTERACTION WITH CCAR2, AND ENZYME REGULATION.
RX   PubMed=18235502; DOI=10.1038/nature06515;
RA   Zhao W., Kruse J.-P., Tang Y., Jung S.Y., Qin J., Gu W.;
RT   "Negative regulation of the deacetylase SIRT1 by DBC1.";
RL   Nature 451:587-590(2008).
RN   [43]
RP   PHOSPHORYLATION AT SER-14; SER-26; SER-27; SER-47; SER-159; SER-162;
RP   SER-172; SER-173; THR-530; THR-544; SER-545; THR-719 AND SER-747, AND
RP   MUTAGENESIS OF THR-530 AND SER-540.
RX   PubMed=19107194; DOI=10.1371/journal.pone.0004020;
RA   Sasaki T., Maier B., Koclega K.D., Chruszcz M., Gluba W.,
RA   Stukenberg P.T., Minor W., Scrable H.;
RT   "Phosphorylation regulates SIRT1 function.";
RL   PLoS ONE 3:E4020-E4020(2008).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-719, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [45]
RP   FUNCTION IN DEACETYLATION OF ATG5; ATG7 AND MAP1LC3B, AND FUNCTION IN
RP   AUTOPHAGY.
RX   PubMed=18296641; DOI=10.1073/pnas.0712145105;
RA   Lee I.H., Cao L., Mostoslavsky R., Lombard D.B., Liu J., Bruns N.E.,
RA   Tsokos M., Alt F.W., Finkel T.;
RT   "A role for the NAD-dependent deacetylase Sirt1 in the regulation of
RT   autophagy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3374-3379(2008).
RN   [46]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [47]
RP   PHOSPHORYLATION AT SER-659 AND SER-661, AND MUTAGENESIS OF SER-659;
RP   SER-661 AND SER-684.
RX   PubMed=19236849; DOI=10.1016/j.bbrc.2009.02.085;
RA   Zschoernig B., Mahlknecht U.;
RT   "Carboxy-terminal phosphorylation of SIRT1 by protein kinase CK2.";
RL   Biochem. Biophys. Res. Commun. 381:372-377(2009).
RN   [48]
RP   FUNCTION.
RX   PubMed=19220062; DOI=10.1021/bi802093g;
RA   Du J., Jiang H., Lin H.;
RT   "Investigating the ADP-ribosyltransferase activity of sirtuins with
RT   NAD analogues and 32P-NAD.";
RL   Biochemistry 48:2878-2890(2009).
RN   [49]
RP   INTERACTION WITH PPARA.
RX   PubMed=19356714; DOI=10.1016/j.cmet.2009.02.006;
RA   Purushotham A., Schug T.T., Xu Q., Surapureddi S., Guo X., Li X.;
RT   "Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism
RT   and results in hepatic steatosis and inflammation.";
RL   Cell Metab. 9:327-338(2009).
RN   [50]
RP   FUNCTION, AND INTERACTION WITH CREBZF.
RX   PubMed=19690166; DOI=10.1074/jbc.M109.034165;
RA   Xie Y.B., Park J.H., Kim D.K., Hwang J.H., Oh S., Park S.B., Shong M.,
RA   Lee I.K., Choi H.S.;
RT   "Transcriptional corepressor SMILE recruits SIRT1 to inhibit nuclear
RT   receptor estrogen receptor-related receptor gamma transactivation.";
RL   J. Biol. Chem. 284:28762-28774(2009).
RN   [51]
RP   FUNCTION IN DEACETYLATION OF MYC, AND FUNCTION IN REGULATION OF MYC.
RX   PubMed=19364925; DOI=10.1083/jcb.200809167;
RA   Yuan J., Minter-Dykhouse K., Lou Z.;
RT   "A c-Myc-SIRT1 feedback loop regulates cell growth and
RT   transformation.";
RL   J. Cell Biol. 185:203-211(2009).
RN   [52]
RP   FUNCTION IN DEACETYLATION OF PCAF, AND FUNCTION IN DNA REPAIR.
RX   PubMed=19188449; DOI=10.1128/MCB.00552-08;
RA   Pediconi N., Guerrieri F., Vossio S., Bruno T., Belloni L.,
RA   Schinzari V., Scisciani C., Fanciulli M., Levrero M.;
RT   "hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in
RT   response to DNA damage.";
RL   Mol. Cell. Biol. 29:1989-1998(2009).
RN   [53]
RP   PHOSPHORYLATION AT SER-27; SER-47 AND THR-530, MUTAGENESIS OF SER-27;
RP   SER-47 AND THR-530, AND SUBCELLULAR LOCATION.
RX   PubMed=20027304; DOI=10.1371/journal.pone.0008414;
RA   Nasrin N., Kaushik V.K., Fortier E., Wall D., Pearson K.J.,
RA   de Cabo R., Bordone L.;
RT   "JNK1 phosphorylates SIRT1 and promotes its enzymatic activity.";
RL   PLoS ONE 4:E8414-E8414(2009).
RN   [54]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-530; SER-535 AND
RP   THR-719, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [55]
RP   FUNCTION IN REGULATION OF STK11.
RX   PubMed=20203304; DOI=10.1161/CIRCRESAHA.109.215483;
RA   Zu Y., Liu L., Lee M.Y., Xu C., Liang Y., Man R.Y., Vanhoutte P.M.,
RA   Wang Y.;
RT   "SIRT1 promotes proliferation and prevents senescence through
RT   targeting LKB1 in primary porcine aortic endothelial cells.";
RL   Circ. Res. 106:1384-1393(2010).
RN   [56]
RP   FUNCTION IN DNA REPAIR HOMOLOGOUS RECOMBINATION.
RX   PubMed=20097625; DOI=10.1016/j.dnarep.2009.12.020;
RA   Uhl M., Csernok A., Aydin S., Kreienberg R., Wiesmuller L., Gatz S.A.;
RT   "Role of SIRT1 in homologous recombination.";
RL   DNA Repair 9:383-393(2010).
RN   [57]
RP   INTERACTION WITH FOS AND JUN.
RX   PubMed=20042607; DOI=10.1074/jbc.M109.038604;
RA   Zhang R., Chen H.Z., Liu J.J., Jia Y.Y., Zhang Z.Q., Yang R.F.,
RA   Zhang Y., Xu J., Wei Y.S., Liu D.P., Liang C.C.;
RT   "SIRT1 suppresses activator protein-1 transcriptional activity and
RT   cyclooxygenase-2 expression in macrophages.";
RL   J. Biol. Chem. 285:7097-7110(2010).
RN   [58]
RP   FUNCTION IN DEACETYLATION OF KAT5.
RX   PubMed=20100829; DOI=10.1074/jbc.M109.087585;
RA   Wang J., Chen J.;
RT   "SIRT1 regulates autoacetylation and histone acetyltransferase
RT   activity of TIP60.";
RL   J. Biol. Chem. 285:11458-11464(2010).
RN   [59]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20167603; DOI=10.1074/jbc.M110.102574;
RA   Guo X., Williams J.G., Schug T.T., Li X.;
RT   "DYRK1A and DYRK3 promote cell survival through phosphorylation and
RT   activation of SIRT1.";
RL   J. Biol. Chem. 285:13223-13232(2010).
RN   [60]
RP   FUNCTION IN DEACETYLATION OF SREBF1.
RX   PubMed=20817729; DOI=10.1074/jbc.M110.122978;
RA   Ponugoti B., Kim D.H., Xiao Z., Smith Z., Miao J., Zang M., Wu S.Y.,
RA   Chiang C.M., Veenstra T.D., Kemper J.K.;
RT   "SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of
RT   hepatic lipid metabolism.";
RL   J. Biol. Chem. 285:33959-33970(2010).
RN   [61]
RP   FUNCTION IN DEACETYLATION OF HIF1A, AND FUNCTION IN REGULATION OF
RP   HIF1A.
RX   PubMed=20620956; DOI=10.1016/j.molcel.2010.05.023;
RA   Lim J.H., Lee Y.M., Chun Y.S., Chen J., Kim J.E., Park J.W.;
RT   "Sirtuin 1 modulates cellular responses to hypoxia by deacetylating
RT   hypoxia-inducible factor 1alpha.";
RL   Mol. Cell 38:864-878(2010).
RN   [62]
RP   FUNCTION IN DEACETYLATION OF XPA.
RX   PubMed=20670893; DOI=10.1016/j.molcel.2010.07.006;
RA   Fan W., Luo J.;
RT   "SIRT1 regulates UV-induced DNA repair through deacetylating XPA.";
RL   Mol. Cell 39:247-258(2010).
RN   [63]
RP   FUNCTION IN DEACETYLATION OF APEX1, FUNCTION IN DNA REPAIR,
RP   MUTAGENESIS OF HIS-363, INDUCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19934257; DOI=10.1093/nar/gkp1039;
RA   Yamamori T., DeRicco J., Naqvi A., Hoffman T.A., Mattagajasingh I.,
RA   Kasuno K., Jung S.B., Kim C.S., Irani K.;
RT   "SIRT1 deacetylates APE1 and regulates cellular base excision
RT   repair.";
RL   Nucleic Acids Res. 38:832-845(2010).
RN   [64]
RP   FUNCTION, AND INTERACTION WITH NR0B2.
RX   PubMed=20375098; DOI=10.1093/nar/gkq227;
RA   Chanda D., Xie Y.B., Choi H.S.;
RT   "Transcriptional corepressor SHP recruits SIRT1 histone deacetylase to
RT   inhibit LRH-1 transactivation.";
RL   Nucleic Acids Res. 38:4607-4619(2010).
RN   [65]
RP   INTERACTION WITH TSC2.
RX   PubMed=20169165; DOI=10.1371/journal.pone.0009199;
RA   Ghosh H.S., McBurney M., Robbins P.D.;
RT   "SIRT1 negatively regulates the mammalian target of rapamycin.";
RL   PLoS ONE 5:E9199-E9199(2010).
RN   [66]
RP   ALTERNATIVE SPLICING (ISOFORM 2), FUNCTION (ISOFORM 2), INDUCTION
RP   (ISOFORM 2), AND INTERACTION WITH TP53 AND RPS19BP1.
RX   PubMed=20975832; DOI=10.1371/journal.pone.0013502;
RA   Lynch C.J., Shah Z.H., Allison S.J., Ahmed S.U., Ford J.,
RA   Warnock L.J., Li H., Serrano M., Milner J.;
RT   "SIRT1 undergoes alternative splicing in a novel auto-regulatory loop
RT   with p53.";
RL   PLoS ONE 5:E13502-E13502(2010).
RN   [67]
RP   FUNCTION IN DNA REPAIR, AND SUPPRESSION OF XPC.
RX   PubMed=21149730; DOI=10.1073/pnas.1010377108;
RA   Ming M., Shea C.R., Guo X., Li X., Soltani K., Han W., He Y.Y.;
RT   "Regulation of global genome nucleotide excision repair by SIRT1
RT   through xeroderma pigmentosum C.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:22623-22628(2010).
RN   [68]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-14 AND SER-47, CLEAVAGE OF INITIATOR METHIONINE
RP   [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [69]
RP   FUNCTION IN DEACETYLATION OF HMGCS1.
RX   PubMed=21701047;
RA   Hirschey M.D., Shimazu T., Capra J.A., Pollard K.S., Verdin E.;
RT   "SIRT1 and SIRT3 deacetylate homologous substrates: AceCS1,2 and
RT   HMGCS1,2.";
RL   Aging (Albany NY) 3:635-642(2011).
RN   [70]
RP   PROCESSING.
RX   PubMed=21305533; DOI=10.1002/art.30279;
RA   Dvir-Ginzberg M., Gagarina V., Lee E.J., Booth R., Gabay O.,
RA   Hall D.J.;
RT   "Tumor necrosis factor alpha-mediated cleavage and inactivation of
RT   SirT1 in human osteoarthritic chondrocytes.";
RL   Arthritis Rheum. 63:2363-2373(2011).
RN   [71]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [72]
RP   FUNCTION IN DEACETYLATION OF XBP1, INTERACTION WITH XBP1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=20955178; DOI=10.1042/BJ20101293;
RA   Wang F.M., Chen Y.J., Ouyang H.J.;
RT   "Regulation of unfolded protein response modulator XBP1s by
RT   acetylation and deacetylation.";
RL   Biochem. J. 433:245-252(2011).
RN   [73]
RP   FUNCTION IN DEACETYLATION OF MECOM.
RX   PubMed=21555002; DOI=10.1016/j.bbagrm.2011.04.007;
RA   Pradhan A.K., Kuila N., Singh S., Chakraborty S.;
RT   "EVI1 up-regulates the stress responsive gene SIRT1 which triggers
RT   deacetylation and degradation of EVI1.";
RL   Biochim. Biophys. Acta 1809:269-275(2011).
RN   [74]
RP   INTERACTION WITH NR1I2.
RX   PubMed=21933665; DOI=10.1016/j.bcp.2011.09.006;
RA   Buler M., Aatsinki S.M., Skoumal R., Hakkola J.;
RT   "Energy sensing factors PGC-1alpha and SIRT1 modulate PXR expression
RT   and function.";
RL   Biochem. Pharmacol. 82:2008-2015(2011).
RN   [75]
RP   FUNCTION IN DEACETYLATION OF MYC, AND FUNCTION IN REGULATION OF MYC.
RX   PubMed=21807113; DOI=10.1016/j.biocel.2011.07.006;
RA   Mao B., Zhao G., Lv X., Chen H.Z., Xue Z., Yang B., Liu D.P.,
RA   Liang C.C.;
RT   "Sirt1 deacetylates c-Myc and promotes c-Myc/Max association.";
RL   Int. J. Biochem. Cell Biol. 43:1573-1581(2011).
RN   [76]
RP   PHOSPHORYLATION BY STK4/MST1.
RX   PubMed=21212262; DOI=10.1074/jbc.M110.182543;
RA   Yuan F., Xie Q., Wu J., Bai Y., Mao B., Dong Y., Bi W., Ji G., Tao W.,
RA   Wang Y., Yuan Z.;
RT   "MST1 promotes apoptosis through regulating Sirt1-dependent p53
RT   deacetylation.";
RL   J. Biol. Chem. 286:6940-6945(2011).
RN   [77]
RP   FUNCTION IN APOPTOSIS, PHOSPHORYLATION AT SER-47, AND MUTAGENESIS OF
RP   SER-47 AND PHE-474.
RX   PubMed=21471201; DOI=10.1074/jbc.M111.240598;
RA   Back J.H., Rezvani H.R., Zhu Y., Guyonnet-Duperat V., Athar M.,
RA   Ratner D., Kim A.L.;
RT   "Cancer cell survival following DNA damage-mediated premature
RT   senescence is regulated by mammalian target of rapamycin (mTOR)-
RT   dependent Inhibition of sirtuin 1.";
RL   J. Biol. Chem. 286:19100-19108(2011).
RN   [78]
RP   FUNCTION IN STABILIZATION OF SUV39H1.
RX   PubMed=21504832; DOI=10.1016/j.molcel.2011.02.034;
RA   Bosch-Presegue L., Raurell-Vila H., Marazuela-Duque A.,
RA   Kane-Goldsmith N., Valle A., Oliver J., Serrano L., Vaquero A.;
RT   "Stabilization of Suv39H1 by SirT1 is part of oxidative stress
RT   response and ensures genome protection.";
RL   Mol. Cell 42:210-223(2011).
RN   [79]
RP   FUNCTION IN DEACETYLATION OF DNMT1, AND FUNCTION IN REGULATION OF
RP   DNMT1.
RX   PubMed=21947282; DOI=10.1128/MCB.06147-11;
RA   Peng L., Yuan Z., Ling H., Fukasawa K., Robertson K., Olashaw N.,
RA   Koomen J., Chen J., Lane W.S., Seto E.;
RT   "SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and
RT   alters its activities.";
RL   Mol. Cell. Biol. 31:4720-4734(2011).
RN   [80]
RP   FUNCTION IN REGULATION OF MYCN, AND INTERACTION WITH MYCN.
RX   PubMed=21698133; DOI=10.1371/journal.pgen.1002135;
RA   Marshall G.M., Liu P.Y., Gherardi S., Scarlett C.J., Bedalov A.,
RA   Xu N., Iraci N., Valli E., Ling D., Thomas W., van Bekkum M.,
RA   Sekyere E., Jankowski K., Trahair T., Mackenzie K.L., Haber M.,
RA   Norris M.D., Biankin A.V., Perini G., Liu T.;
RT   "SIRT1 promotes N-Myc oncogenesis through a positive feedback loop
RT   involving the effects of MKP3 and ERK on N-Myc protein stability.";
RL   PLoS Genet. 7:E1002135-E1002135(2011).
RN   [81]
RP   INTERACTION WITH HCFC1.
RX   PubMed=21909281; DOI=10.1371/journal.pgen.1002235;
RA   Rizki G., Iwata T.N., Li J., Riedel C.G., Picard C.L., Jan M.,
RA   Murphy C.T., Lee S.S.;
RT   "The evolutionarily conserved longevity determinants HCF-1 and SIR-
RT   2.1/SIRT1 collaborate to regulate DAF-16/FOXO.";
RL   PLoS Genet. 7:E1002235-E1002235(2011).
RN   [82]
RP   INTERACTION WITH SETD7, AND MUTAGENESIS OF LYS-233; LYS-235; LYS-236
RP   AND LYS-238.
RX   PubMed=21245319; DOI=10.1073/pnas.1019619108;
RA   Liu X., Wang D., Zhao Y., Tu B., Zheng Z., Wang L., Wang H., Gu W.,
RA   Roeder R.G., Zhu W.G.;
RT   "Methyltransferase Set7/9 regulates p53 activity by interacting with
RT   Sirtuin 1 (SIRT1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:1925-1930(2011).
RN   [83]
RP   FUNCTION IN DEACETYLATION OF AKT1, AND FUNCTION IN REGULATION OF AKT1.
RX   PubMed=21775285; DOI=10.1126/scisignal.2001465;
RA   Sundaresan N.R., Pillai V.B., Wolfgeher D., Samant S., Vasudevan P.,
RA   Parekh V., Raghuraman H., Cunningham J.M., Gupta M., Gupta M.P.;
RT   "The deacetylase SIRT1 promotes membrane localization and activation
RT   of Akt and PDK1 during tumorigenesis and cardiac hypertrophy.";
RL   Sci. Signal. 4:RA46-RA46(2011).
RN   [84]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-14; SER-47 AND THR-719, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [85]
RP   FUNCTION (SIRTT1 75 KDA FRAGMENT), AND SUBCELLULAR LOCATION (75SIRT1).
RX   PubMed=21987377; DOI=10.1002/art.33407;
RA   Oppenheimer H., Gabay O., Meir H., Haze A., Kandel L., Liebergall M.,
RA   Gagarina V., Lee E.J., Dvir-Ginzberg M.;
RT   "75kDa SirT1 blocks TNFalpha-mediated apoptosis in human
RT   osteoarthritic chondrocytes.";
RL   Arthritis Rheum. 64:718-728(2012).
RN   [86]
RP   FUNCTION IN DEACETYLATION OF CIITA.
RX   PubMed=21890893; DOI=10.1093/nar/gkr651;
RA   Wu X., Kong X., Chen D., Li H., Zhao Y., Xia M., Fang M., Li P.,
RA   Fang F., Sun L., Tian W., Xu H., Yang Y., Qi X., Gao Y., Sha J.,
RA   Chen Q., Xu Y.;
RT   "SIRT1 links CIITA deacetylation to MHC II activation.";
RL   Nucleic Acids Res. 39:9549-9558(2011).
RN   [87]
RP   FUNCTION IN DEACETYLATION OF PML.
RX   PubMed=22274616; DOI=10.1038/emboj.2012.1;
RA   Miki T., Xu Z., Chen-Goodspeed M., Liu M., Van Oort-Jansen A.,
RA   Rea M.A., Zhao Z., Lee C.C., Chang K.S.;
RT   "PML regulates PER2 nuclear localization and circadian function.";
RL   EMBO J. 31:1427-1439(2012).
RN   [88]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [89]
RP   FUNCTION IN DEACETYLATION OF FOXO3, AND FUNCTION IN REGULATION OF
RP   FOXO3.
RX   PubMed=21841822; DOI=10.1038/onc.2011.347;
RA   Wang F., Chan C.H., Chen K., Guan X., Lin H.K., Tong Q.;
RT   "Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3
RT   ubiquitination and degradation.";
RL   Oncogene 31:1546-1557(2012).
RN   [90]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [91]
RP   INTERACTION WITH CCAR2.
RX   PubMed=23352644; DOI=10.1016/j.canlet.2013.01.026;
RA   Kim W., Kim J.E.;
RT   "Deleted in breast cancer 1 (DBC1) deficiency results in apoptosis of
RT   breast cancer cells through impaired responses to UV-induced DNA
RT   damage.";
RL   Cancer Lett. 333:180-186(2013).
RN   [92]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-27; SER-47 AND
RP   THR-719, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [93]
RP   INTERACTION WITH PPARA.
RX   PubMed=24043310; DOI=10.1128/MCB.00087-13;
RA   Laurent G., de Boer V.C., Finley L.W., Sweeney M., Lu H., Schug T.T.,
RA   Cen Y., Jeong S.M., Li X., Sauve A.A., Haigis M.C.;
RT   "SIRT4 represses peroxisome proliferator-activated receptor alpha
RT   activity to suppress hepatic fat oxidation.";
RL   Mol. Cell. Biol. 33:4552-4561(2013).
RN   [94]
RP   FUNCTION.
RX   PubMed=24415752; DOI=10.1074/jbc.M113.512913;
RA   Nin V., Chini C.C., Escande C., Capellini V., Chini E.N.;
RT   "Deleted in breast cancer 1 (DBC1) protein regulates hepatic
RT   gluconeogenesis.";
RL   J. Biol. Chem. 289:5518-5527(2014).
RN   [95]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14 AND SER-27, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [96]
RP   INTERACTION WITH CCAR2 AND TP53, AND MUTAGENESIS OF 256-ILE-ILE-257
RP   AND HIS-363.
RX   PubMed=25406032; DOI=10.1038/ncomms6483;
RA   Park J.H., Lee S.W., Yang S.W., Yoo H.M., Park J.M., Seong M.W.,
RA   Ka S.H., Oh K.H., Jeon Y.J., Chung C.H.;
RT   "Modification of DBC1 by SUMO2/3 is crucial for p53-mediated apoptosis
RT   in response to DNA damage.";
RL   Nat. Commun. 5:5483-5483(2014).
RN   [97]
RP   INTERACTION WITH CHEK2.
RX   PubMed=25361978; DOI=10.1093/nar/gku1065;
RA   Magni M., Ruscica V., Buscemi G., Kim J.E., Nachimuthu B.T.,
RA   Fontanella E., Delia D., Zannini L.;
RT   "Chk2 and REGgamma-dependent DBC1 regulation in DNA damage induced
RT   apoptosis.";
RL   Nucleic Acids Res. 42:13150-13160(2014).
RN   [98]
RP   FUNCTION IN DEACETYLATION OF CTNB1.
RX   PubMed=24824780; DOI=10.1002/ijc.28967;
RA   Pangon L., Mladenova D., Watkins L., Van Kralingen C., Currey N.,
RA   Al-Sohaily S., Lecine P., Borg J.P., Kohonen-Corish M.R.;
RT   "MCC inhibits beta-catenin transcriptional activity by sequestering
RT   DBC1 in the cytoplasm.";
RL   Int. J. Cancer 136:55-64(2015).
RN   [99]
RP   INTERACTION WITH NR1H3.
RX   PubMed=25661920; DOI=10.1016/j.jsbmb.2015.02.001;
RA   Sakurabashi A., Wada-Hiraike O., Hirano M., Fu H., Isono W.,
RA   Fukuda T., Morita Y., Tanikawa M., Miyamoto Y., Oda K., Kawana K.,
RA   Osuga Y., Fujii T.;
RT   "CCAR2 negatively regulates nuclear receptor LXRalpha by competing
RT   with SIRT1 deacetylase.";
RL   J. Steroid Biochem. Mol. Biol. 149:80-88(2015).
CC   -!- FUNCTION: NAD-dependent protein deacetylase that links
CC       transcriptional regulation directly to intracellular energetics
CC       and participates in the coordination of several separated cellular
CC       functions such as cell cycle, response to DNA damage, metobolism,
CC       apoptosis and autophagy. Can modulate chromatin function through
CC       deacetylation of histones and can promote alterations in the
CC       methylation of histones and DNA, leading to transcriptional
CC       repression. Deacetylates a broad range of transcription factors
CC       and coregulators, thereby regulating target gene expression
CC       positively and negatively. Serves as a sensor of the cytosolic
CC       ratio of NAD(+)/NADH which is altered by glucose deprivation and
CC       metabolic changes associated with caloric restriction. Is
CC       essential in skeletal muscle cell differentiation and in response
CC       to low nutrients mediates the inhibitory effect on skeletal
CC       myoblast differentiation which also involves 5'-AMP-activated
CC       protein kinase (AMPK) and nicotinamide phosphoribosyltransferase
CC       (NAMPT). Component of the eNoSC (energy-dependent nucleolar
CC       silencing) complex, a complex that mediates silencing of rDNA in
CC       response to intracellular energy status and acts by recruiting
CC       histone-modifying enzymes. The eNoSC complex is able to sense the
CC       energy status of cell: upon glucose starvation, elevation of
CC       NAD(+)/NADP(+) ratio activates SIRT1, leading to histone H3
CC       deacetylation followed by dimethylation of H3 at 'Lys-9' (H3K9me2)
CC       by SUV39H1 and the formation of silent chromatin in the rDNA
CC       locus. Deacetylates 'Lys-266' of SUV39H1, leading to its
CC       activation. Inhibits skeletal muscle differentiation by
CC       deacetylating PCAF and MYOD1. Deacetylates H2A and 'Lys-26' of
CC       HIST1H1E. Deacetylates 'Lys-16' of histone H4 (in vitro). Involved
CC       in NR0B2/SHP corepression function through chromatin remodeling:
CC       Recruited to LRH1 target gene promoters by NR0B2/SHP thereby
CC       stimulating histone H3 and H4 deacetylation leading to
CC       transcriptional repression. Proposed to contribute to genomic
CC       integrity via positive regulation of telomere length; however,
CC       reports on localization to pericentromeric heterochromatin are
CC       conflicting. Proposed to play a role in constitutive
CC       heterochromatin (CH) formation and/or maintenance through
CC       regulation of the available pool of nuclear SUV39H1. Upon
CC       oxidative/metabolic stress decreases SUV39H1 degradation by
CC       inhibiting SUV39H1 polyubiquitination by MDM2. This increase in
CC       SUV39H1 levels enhances SUV39H1 turnover in CH, which in turn
CC       seems to accelerate renewal of the heterochromatin which
CC       correlates with greater genomic integrity during stress response.
CC       Deacetylates 'Lys-382' of p53/TP53 and impairs its ability to
CC       induce transcription-dependent proapoptotic program and modulate
CC       cell senescence. Deacetylates TAF1B and thereby represses rDNA
CC       transcription by the RNA polymerase I. Deacetylates MYC, promotes
CC       the association of MYC with MAX and decreases MYC stability
CC       leading to compromised transformational capability. Deacetylates
CC       FOXO3 in response to oxidative stress thereby increasing its
CC       ability to induce cell cycle arrest and resistance to oxidative
CC       stress but inhibiting FOXO3-mediated induction of apoptosis
CC       transcriptional activity; also leading to FOXO3 ubiquitination and
CC       protesomal degradation. Appears to have a similar effect on
CC       MLLT7/FOXO4 in regulation of transcriptional activity and
CC       apoptosis. Deacetylates DNMT1; thereby impairs DNMT1
CC       methyltransferase-independent transcription repressor activity,
CC       modulates DNMT1 cell cycle regulatory function and DNMT1-mediated
CC       gene silencing. Deacetylates RELA/NF-kappa-B p65 thereby
CC       inhibiting its transactivating potential and augments apoptosis in
CC       response to TNF-alpha. Deacetylates HIF1A, KAT5/TIP60, RB1 and
CC       HIC1. Deacetylates FOXO1 resulting in its nuclear retention and
CC       enhancement of its transcriptional activity leading to increased
CC       gluconeogenesis in liver. Inhibits E2F1 transcriptional activity
CC       and apoptotic function, possibly by deacetylation. Involved in
CC       HES1- and HEY2-mediated transcriptional repression. In cooperation
CC       with MYCN seems to be involved in transcriptional repression of
CC       DUSP6/MAPK3 leading to MYCN stabilization by phosphorylation at
CC       'Ser-62'. Deacetylates MEF2D. Required for antagonist-mediated
CC       transcription suppression of AR-dependent genes which may be
CC       linked to local deacetylation of histone H3. Represses HNF1A-
CC       mediated transcription. Required for the repression of ESRRG by
CC       CREBZF. Modulates AP-1 transcription factor activity. Deacetylates
CC       NR1H3 AND NR1H2 and deacetylation of NR1H3 at 'Lys-434' positively
CC       regulates transcription of NR1H3:RXR target genes, promotes NR1H3
CC       proteosomal degradation and results in cholesterol efflux; a
CC       promoter clearing mechanism after reach round of transcription is
CC       proposed. Involved in lipid metabolism. Implicated in regulation
CC       of adipogenesis and fat mobilization in white adipocytes by
CC       repression of PPARG which probably involves association with NCOR1
CC       and SMRT/NCOR2. Deacetylates ACSS2 leading to its activation, and
CC       HMGCS1. Involved in liver and muscle metabolism. Through
CC       deacteylation and activation of PPARGC1A is required to activate
CC       fatty acid oxidation in skeletel muscle under low-glucose
CC       conditions and is involved in glucose homeostasis. Involved in
CC       regulation of PPARA and fatty acid beta-oxidation in liver.
CC       Involved in positive regulation of insulin secretion in pancreatic
CC       beta cells in response to glucose; the function seems to imply
CC       transcriptional repression of UCP2. Proposed to deacetylate IRS2
CC       thereby facilitating its insulin-induced tyrosine phosphorylation.
CC       Deacetylates SREBF1 isoform SREBP-1C thereby decreasing its
CC       stability and transactivation in lipogenic gene expression.
CC       Involved in DNA damage response by repressing genes which are
CC       involved in DNA repair, such as XPC and TP73, deacetylating
CC       XRCC6/Ku70, and faciliting recruitment of additional factors to
CC       sites of damaged DNA, such as SIRT1-deacetylated NBN can recruit
CC       ATM to initiate DNA repair and SIRT1-deacetylated XPA interacts
CC       with RPA2. Also involved in DNA repair of DNA double-strand breaks
CC       by homologous recombination and specifically single-strand
CC       annealing independently of XRCC6/Ku70 and NBN. Transcriptional
CC       suppression of XPC probably involves an E2F4:RBL2 suppressor
CC       complex and protein kinase B (AKT) signaling. Transcriptional
CC       suppression of TP73 probably involves E2F4 and PCAF. Deacetylates
CC       WRN thereby regulating its helicase and exonuclease activities and
CC       regulates WRN nuclear translocation in response to DNA damage.
CC       Deacetylates APEX1 at 'Lys-6' and 'Lys-7' and stimulates cellular
CC       AP endonuclease activity by promoting the association of APEX1 to
CC       XRCC1. Increases p53/TP53-mediated transcription-independent
CC       apoptosis by blocking nuclear translocation of cytoplasmic
CC       p53/TP53 and probably redirecting it to mitochondria. Deacetylates
CC       XRCC6/Ku70 at 'Lys-539' and 'Lys-542' causing it to sequester BAX
CC       away from mitochondria thereby inhibiting stress-induced
CC       apoptosis. Is involved in autophagy, presumably by deacetylating
CC       ATG5, ATG7 and MAP1LC3B/ATG8. Deacetylates AKT1 which leads to
CC       enhanced binding of AKT1 and PDK1 to PIP3 and promotes their
CC       activation. Proposed to play role in regulation of STK11/LBK1-
CC       dependent AMPK signaling pathways implicated in cellular
CC       senescence which seems to involve the regulation of the
CC       acetylation status of STK11/LBK1. Can deacetylate STK11/LBK1 and
CC       thereby increase its activity, cytoplasmic localization and
CC       association with STRAD; however, the relevance of such activity in
CC       normal cells is unclear. In endothelial cells is shown to inhibit
CC       STK11/LBK1 activity and to promote its degradation. Deacetylates
CC       SMAD7 at 'Lys-64' and 'Lys-70' thereby promoting its degradation.
CC       Deacetylates CIITA and augments its MHC class II transactivation
CC       and contributes to its stability. Deacteylates MECOM/EVI1.
CC       Deacetylates PML at 'Lys-487' and this deacetylation promotes PML
CC       control of PER2 nuclear localization. During the neurogenic
CC       transition, repress selective NOTCH1-target genes through histone
CC       deacetylation in a BCL6-dependent manner and leading to neuronal
CC       differentiation. Regulates the circadian expression of several
CC       core clock genes, including ARNTL/BMAL1, RORC, PER2 and CRY1 and
CC       plays a critical role in maintaining a controlled rhythmicity in
CC       histone acetylation, thereby contributing to circadian chromatin
CC       remodeling. Deacetylates ARNTL/BMAL1 and histones at the circadian
CC       gene promoters in order to facilitate repression by inhibitory
CC       components of the circadian oscillator. Deacetylates PER2,
CC       facilitating its ubiquitination and degradation by the proteosome.
CC       Protects cardiomyocytes against palmitate-induced apoptosis
CC       (PubMed:11672523, PubMed:12006491, PubMed:14976264,
CC       PubMed:14980222, PubMed:15126506, PubMed:15152190,
CC       PubMed:15205477, PubMed:15469825, PubMed:15692560,
CC       PubMed:16079181, PubMed:16166628, PubMed:16892051,
CC       PubMed:16998810, PubMed:17283066, PubMed:17334224,
CC       PubMed:17505061, PubMed:17612497, PubMed:17620057,
CC       PubMed:17936707, PubMed:18203716, PubMed:18296641,
CC       PubMed:18662546, PubMed:18687677, PubMed:19188449,
CC       PubMed:19220062, PubMed:19364925, PubMed:19690166,
CC       PubMed:19934257, PubMed:20097625, PubMed:20100829,
CC       PubMed:20203304, PubMed:20375098, PubMed:20620956,
CC       PubMed:20670893, PubMed:20817729, PubMed:21149730,
CC       PubMed:21245319, PubMed:21471201, PubMed:21504832,
CC       PubMed:21555002, PubMed:21698133, PubMed:21701047,
CC       PubMed:21775285, PubMed:21807113, PubMed:21841822,
CC       PubMed:21890893, PubMed:21909281, PubMed:21947282,
CC       PubMed:22274616). Deacetylates XBP1 isoform 2; deacetylation
CC       decreases protein stability of XBP1 isoform 2 and inhibits its
CC       transcriptional activity (PubMed:20955178). Involved in the CCAR2-
CC       mediated regulation of PCK1 and NR1D1 (PubMed:24415752).
CC       Deacetylates CTNB1 at 'Lys-49' (PubMed:24824780). In POMC (pro-
CC       opiomelanocortin) neurons, required for leptin-induced activation
CC       of PI3K signaling (By similarity). {ECO:0000250|UniProtKB:Q923E4,
CC       ECO:0000269|PubMed:11672523, ECO:0000269|PubMed:12006491,
CC       ECO:0000269|PubMed:14976264, ECO:0000269|PubMed:14980222,
CC       ECO:0000269|PubMed:15126506, ECO:0000269|PubMed:15152190,
CC       ECO:0000269|PubMed:15205477, ECO:0000269|PubMed:15469825,
CC       ECO:0000269|PubMed:15692560, ECO:0000269|PubMed:16079181,
CC       ECO:0000269|PubMed:16166628, ECO:0000269|PubMed:16892051,
CC       ECO:0000269|PubMed:16998810, ECO:0000269|PubMed:17283066,
CC       ECO:0000269|PubMed:17290224, ECO:0000269|PubMed:17334224,
CC       ECO:0000269|PubMed:17505061, ECO:0000269|PubMed:17612497,
CC       ECO:0000269|PubMed:17620057, ECO:0000269|PubMed:17936707,
CC       ECO:0000269|PubMed:18203716, ECO:0000269|PubMed:18296641,
CC       ECO:0000269|PubMed:18662546, ECO:0000269|PubMed:18687677,
CC       ECO:0000269|PubMed:19188449, ECO:0000269|PubMed:19220062,
CC       ECO:0000269|PubMed:19364925, ECO:0000269|PubMed:19690166,
CC       ECO:0000269|PubMed:19934257, ECO:0000269|PubMed:20097625,
CC       ECO:0000269|PubMed:20100829, ECO:0000269|PubMed:20203304,
CC       ECO:0000269|PubMed:20375098, ECO:0000269|PubMed:20620956,
CC       ECO:0000269|PubMed:20670893, ECO:0000269|PubMed:20817729,
CC       ECO:0000269|PubMed:20955178, ECO:0000269|PubMed:21149730,
CC       ECO:0000269|PubMed:21245319, ECO:0000269|PubMed:21471201,
CC       ECO:0000269|PubMed:21504832, ECO:0000269|PubMed:21555002,
CC       ECO:0000269|PubMed:21698133, ECO:0000269|PubMed:21701047,
CC       ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:21807113,
CC       ECO:0000269|PubMed:21841822, ECO:0000269|PubMed:21890893,
CC       ECO:0000269|PubMed:21909281, ECO:0000269|PubMed:21947282,
CC       ECO:0000269|PubMed:22274616, ECO:0000269|PubMed:24415752,
CC       ECO:0000269|PubMed:24824780}.
CC   -!- FUNCTION: Isoform 2: Isoform 2 is shown to deacetylate 'Lys-382'
CC       of p53/TP53, however with lower activity than isoform 1. In
CC       combination, the two isoforms exert an additive effect. Isoform 2
CC       regulates p53/TP53 expression and cellular stress response and is
CC       in turn repressed by p53/TP53 presenting a SIRT1 isoform-dependent
CC       auto-regulatory loop. {ECO:0000269|PubMed:20975832}.
CC   -!- FUNCTION: (Microbial infection) In case of HIV-1 infection,
CC       interacts with and deacetylates the viral Tat protein. The viral
CC       Tat protein inhibits SIRT1 deacetylation activity toward RELA/NF-
CC       kappa-B p65, thereby potentiates its transcriptional activity and
CC       SIRT1 is proposed to contribute to T-cell hyperactivation during
CC       infection. {ECO:0000269|PubMed:18329615}.
CC   -!- FUNCTION: SirtT1 75 kDa fragment: catalytically inactive 75SirT1
CC       may be involved in regulation of apoptosis. May be involved in
CC       protecting chondrocytes from apoptotic death by associating with
CC       cytochrome C and interfering with apoptosome assembly.
CC       {ECO:0000269|PubMed:21987377}.
CC   -!- CATALYTIC ACTIVITY: NAD(+) + an acetylprotein = nicotinamide + O-
CC       acetyl-ADP-ribose + a protein. {ECO:0000255|PROSITE-
CC       ProRule:PRU00236, ECO:0000269|PubMed:12006491}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- ENZYME REGULATION: Inhibited by nicotinamide. Activated by
CC       resveratrol (3,5,4'-trihydroxy-trans-stilbene), butein (3,4,2',4'-
CC       tetrahydroxychalcone), piceatannol (3,5,3',4'-tetrahydroxy-trans-
CC       stilbene), Isoliquiritigenin (4,2',4'-trihydroxychalcone), fisetin
CC       (3,7,3',4'-tetrahydroxyflavone) and quercetin (3,5,7,3',4'-
CC       pentahydroxyflavone). MAPK8/JNK1 and RPS19BP1/AROS act as positive
CC       regulators of deacetylation activity. Negatively regulated by
CC       CCAR2. {ECO:0000269|PubMed:12297502, ECO:0000269|PubMed:12939617,
CC       ECO:0000269|PubMed:18235501, ECO:0000269|PubMed:18235502}.
CC   -!- SUBUNIT: Interacts with XBP1 isoform 2 (PubMed:20955178). Found in
CC       a complex with PCAF and MYOD1. Interacts with FOXO1; the
CC       interaction deacetylates FOXO1, resulting in its nuclear retention
CC       and promotion of its transcriptional activity Component of the
CC       eNoSC complex, composed of SIRT1, SUV39H1 and RRP8. Interacts with
CC       HES1, HEY2 and PML. Interacts with RPS19BP1/AROS. Interacts with
CC       CCAR2 (via N-terminus); the interaction disrupts the interaction
CC       between SIRT1 and p53/TP53. Interacts with SETD7; the interaction
CC       induces the dissociation of SIRT1 from p53/TP53 and increases
CC       p53/TP53 activity. Interacts with MYCN, NR1I2, CREBZF, TSC2, TLE1,
CC       FOS, JUN, NR0B2, PPARG, NCOR, IRS1, IRS2 and NMNAT1. Interacts
CC       with HNF1A; the interaction occurs under nutrient restriction.
CC       Interacts with SUZ12; the interaction mediates the association
CC       with the PRC4 histone methylation complex which is specific as an
CC       association with PCR2 and PCR3 complex variants is not found.
CC       Interacts with HIV-1 tat. Interacts with BCL6; leads to a
CC       epigenetic repression of specific target genes. Interacts with
CC       CLOCK, ARNTL/BMAL1 and PER2 (By similarity). Interacts with PPARA;
CC       the interaction seems to be modulated by NAD(+) levels
CC       (PubMed:24043310). Interacts with NR1H3 and this interaction is
CC       inhibited in the presence of CCAR2. Interacts with CHEK2.
CC       Interacts with p53/TP53. Exhibits a preferential interaction with
CC       sumoylated CCAR2 over its unmodified form.
CC       {ECO:0000250|UniProtKB:Q923E4, ECO:0000269|PubMed:12006491,
CC       ECO:0000269|PubMed:12535671, ECO:0000269|PubMed:15684044,
CC       ECO:0000269|PubMed:15692560, ECO:0000269|PubMed:15719057,
CC       ECO:0000269|PubMed:16166628, ECO:0000269|PubMed:16892051,
CC       ECO:0000269|PubMed:17680780, ECO:0000269|PubMed:17964266,
CC       ECO:0000269|PubMed:18235501, ECO:0000269|PubMed:18235502,
CC       ECO:0000269|PubMed:18329615, ECO:0000269|PubMed:18485871,
CC       ECO:0000269|PubMed:19356714, ECO:0000269|PubMed:19690166,
CC       ECO:0000269|PubMed:20042607, ECO:0000269|PubMed:20169165,
CC       ECO:0000269|PubMed:20375098, ECO:0000269|PubMed:20955178,
CC       ECO:0000269|PubMed:20975832, ECO:0000269|PubMed:21245319,
CC       ECO:0000269|PubMed:21698133, ECO:0000269|PubMed:21909281,
CC       ECO:0000269|PubMed:21933665, ECO:0000269|PubMed:23352644,
CC       ECO:0000269|PubMed:24043310, ECO:0000269|PubMed:25361978,
CC       ECO:0000269|PubMed:25406032, ECO:0000269|PubMed:25661920}.
CC   -!- INTERACTION:
CC       Q13085:ACACA; NbExp=3; IntAct=EBI-1802965, EBI-717681;
CC       P31749:AKT1; NbExp=5; IntAct=EBI-1802965, EBI-296087;
CC       P27695:APEX1; NbExp=6; IntAct=EBI-1802965, EBI-1048805;
CC       Q8N163:CCAR2; NbExp=9; IntAct=EBI-1802965, EBI-355410;
CC       P33076:CIITA; NbExp=4; IntAct=EBI-1802965, EBI-1538819;
CC       Q9NS37:CREBZF; NbExp=3; IntAct=EBI-1802965, EBI-632965;
CC       P68400:CSNK2A1; NbExp=4; IntAct=EBI-1802965, EBI-347804;
CC       P67870:CSNK2B; NbExp=5; IntAct=EBI-1802965, EBI-348169;
CC       P26358:DNMT1; NbExp=11; IntAct=EBI-1802965, EBI-719459;
CC       Q01094:E2F1; NbExp=3; IntAct=EBI-1802965, EBI-448924;
CC       Q09472:EP300; NbExp=2; IntAct=EBI-1802965, EBI-447295;
CC       Q14192:FHL2; NbExp=2; IntAct=EBI-1802965, EBI-701903;
CC       Q12778:FOXO1; NbExp=3; IntAct=EBI-1802965, EBI-1108782;
CC       Q9R1E0:Foxo1 (xeno); NbExp=2; IntAct=EBI-1802965, EBI-1371343;
CC       O43524:FOXO3; NbExp=5; IntAct=EBI-1802965, EBI-1644164;
CC       P98177:FOXO4; NbExp=3; IntAct=EBI-1802965, EBI-4481939;
CC       P51610:HCFC1; NbExp=2; IntAct=EBI-1802965, EBI-396176;
CC       Q14469:HES1; NbExp=4; IntAct=EBI-1802965, EBI-2832522;
CC       Q9UBP5:HEY2; NbExp=3; IntAct=EBI-1802965, EBI-750630;
CC       Q9Y4H2:IRS2; NbExp=2; IntAct=EBI-1802965, EBI-1049582;
CC       Q92831:KAT2B; NbExp=3; IntAct=EBI-1802965, EBI-477430;
CC       Q03112:MECOM; NbExp=2; IntAct=EBI-1802965, EBI-1384862;
CC       P42345:MTOR; NbExp=2; IntAct=EBI-1802965, EBI-359260;
CC       P01106:MYC; NbExp=4; IntAct=EBI-1802965, EBI-447544;
CC       P04198:MYCN; NbExp=3; IntAct=EBI-1802965, EBI-878369;
CC       O60934:NBN; NbExp=5; IntAct=EBI-1802965, EBI-494844;
CC       Q60974:Ncor1 (xeno); NbExp=2; IntAct=EBI-1802965, EBI-349004;
CC       Q02577:NHLH2; NbExp=2; IntAct=EBI-1802965, EBI-5378683;
CC       Q9HAN9:NMNAT1; NbExp=3; IntAct=EBI-1802965, EBI-3917542;
CC       Q15466:NR0B2; NbExp=6; IntAct=EBI-1802965, EBI-3910729;
CC       Q60644:Nr1h2 (xeno); NbExp=2; IntAct=EBI-1802965, EBI-5276809;
CC       Q9Z0Y9:Nr1h3 (xeno); NbExp=2; IntAct=EBI-1802965, EBI-5276764;
CC       P27986:PIK3R1; NbExp=3; IntAct=EBI-1802965, EBI-79464;
CC       P37238:Pparg (xeno); NbExp=3; IntAct=EBI-1802965, EBI-5260705;
CC       P37238-1:Pparg (xeno); NbExp=2; IntAct=EBI-1802965, EBI-6267861;
CC       P10276:RARA; NbExp=3; IntAct=EBI-1802965, EBI-413374;
CC       Q04206:RELA; NbExp=5; IntAct=EBI-1802965, EBI-73886;
CC       Q86WX3:RPS19BP1; NbExp=11; IntAct=EBI-1802965, EBI-4479407;
CC       Q8N122:RPTOR; NbExp=3; IntAct=EBI-1802965, EBI-1567928;
CC       O43159:RRP8; NbExp=3; IntAct=EBI-1802965, EBI-2008793;
CC       Q13573:SNW1; NbExp=7; IntAct=EBI-1802965, EBI-632715;
CC       P36956-3:SREBF1; NbExp=2; IntAct=EBI-1802965, EBI-948338;
CC       O54864:Suv39h1 (xeno); NbExp=4; IntAct=EBI-1802965, EBI-302230;
CC       P04608:tat (xeno); NbExp=3; IntAct=EBI-1802965, EBI-6164389;
CC       Q04724:TLE1; NbExp=4; IntAct=EBI-1802965, EBI-711424;
CC       P04637:TP53; NbExp=13; IntAct=EBI-1802965, EBI-366083;
CC       O15350:TP73; NbExp=4; IntAct=EBI-1802965, EBI-389606;
CC       P49815:TSC2; NbExp=2; IntAct=EBI-1802965, EBI-396587;
CC       Q14191:WRN; NbExp=9; IntAct=EBI-1802965, EBI-368417;
CC       P23025:XPA; NbExp=8; IntAct=EBI-1802965, EBI-295222;
CC       P12956:XRCC6; NbExp=7; IntAct=EBI-1802965, EBI-353208;
CC   -!- SUBCELLULAR LOCATION: Nucleus, PML body
CC       {ECO:0000269|PubMed:12006491}. Cytoplasm
CC       {ECO:0000269|PubMed:20027304}. Nucleus
CC       {ECO:0000269|PubMed:11672523, ECO:0000269|PubMed:15469825,
CC       ECO:0000269|PubMed:16079181, ECO:0000269|PubMed:19934257,
CC       ECO:0000269|PubMed:20027304, ECO:0000269|PubMed:20167603,
CC       ECO:0000269|PubMed:20955178}. Note=Recruited to the nuclear bodies
CC       via its interaction with PML (PubMed:12006491). Colocalized with
CC       APEX1 in the nucleus (PubMed:19934257). May be found in nucleolus,
CC       nuclear euchromatin, heterochromatin and inner membrane
CC       (PubMed:15469825). Shuttles between nucleus and cytoplasm (By
CC       similarity). Colocalizes in the nucleus with XBP1 isoform 2
CC       (PubMed:20955178). {ECO:0000250|UniProtKB:Q923E4,
CC       ECO:0000269|PubMed:12006491, ECO:0000269|PubMed:15469825,
CC       ECO:0000269|PubMed:19934257, ECO:0000269|PubMed:20955178}.
CC   -!- SUBCELLULAR LOCATION: SirtT1 75 kDa fragment: Cytoplasm
CC       {ECO:0000269|PubMed:21987377}. Mitochondrion
CC       {ECO:0000269|PubMed:21987377}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96EB6-1; Sequence=Displayed;
CC       Name=2; Synonyms=delta-exon8;
CC         IsoId=Q96EB6-2; Sequence=VSP_042189;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC       {ECO:0000269|PubMed:10381378}.
CC   -!- INDUCTION: Up-regulated by methyl methanesulfonate (MMS). In H293T
CC       cells by presence of rat calorie restriction (CR) serum.
CC       {ECO:0000269|PubMed:15205477, ECO:0000269|PubMed:19934257}.
CC   -!- PTM: Methylated on multiple lysine residues; methylation is
CC       enhanced after DNA damage and is dispensable for deacetylase
CC       activity toward p53/TP53.
CC   -!- PTM: Phosphorylated. Phosphorylated by STK4/MST1, resulting in
CC       inhibition of SIRT1-mediated p53/TP53 deacetylation.
CC       Phosphorylation by MAPK8/JNK1 at Ser-27, Ser-47, and Thr-530 leads
CC       to increased nuclear localization and enzymatic activity.
CC       Phosphorylation at Thr-530 by DYRK1A and DYRK3 activates
CC       deacetylase activity and promotes cell survival. Phosphorylation
CC       by mammalian target of rapamycin complex 1 (mTORC1) at Ser-47
CC       inhibits deacetylation activity. Phosphorylated by CaMK2, leading
CC       to increased p53/TP53 and NF-kappa-B p65/RELA deacetylation
CC       activity (By similarity). Phosphorylation at Ser-27 implicating
CC       MAPK9 is linked to protein stability. There is some ambiguity for
CC       some phosphosites: Ser-159/Ser-162 and Thr-544/Ser-545.
CC       {ECO:0000250|UniProtKB:Q923E4, ECO:0000269|PubMed:18838864,
CC       ECO:0000269|PubMed:19107194, ECO:0000269|PubMed:19236849,
CC       ECO:0000269|PubMed:20027304, ECO:0000269|PubMed:21212262,
CC       ECO:0000269|PubMed:21471201}.
CC   -!- PTM: Proteolytically cleaved by cathepsin B upon TNF-alpha
CC       treatment to yield catalytic inactive but stable SirtT1 75 kDa
CC       fragment (75SirT1).
CC   -!- PTM: S-nitrosylated by GAPDH, leading to inhibit the NAD-dependent
CC       protein deacetylase activity. {ECO:0000250}.
CC   -!- MISCELLANEOUS: Red wine, which contains resveratrol, may
CC       participate in activation of sirtuin proteins, and may therefore
CC       participate in an extended lifespan as it has been observed in
CC       yeast.
CC   -!- MISCELLANEOUS: Calf histone H1 is used as substrate in the in
CC       vitro deacetylation assay (PubMed:15469825). As, in vivo,
CC       interaction occurs between SIRT1 with HIST1H1E, deacetylation has
CC       been validated only for HIST1H1E. {ECO:0000305|PubMed:15469825}.
CC   -!- MISCELLANEOUS: The reported ADP-ribosyltransferase activity of
CC       sirtuins is likely some inefficient side reaction of the
CC       deacetylase activity and may not be physiologically relevant.
CC       {ECO:0000305|PubMed:19220062}.
CC   -!- SIMILARITY: Belongs to the sirtuin family. Class I subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH12499.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/sirt1/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SIRT1ID44006ch10q21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF083106; AAD40849.2; -; mRNA.
DR   EMBL; AF235040; AAG38486.1; -; mRNA.
DR   EMBL; DQ278604; ABB72675.1; -; Genomic_DNA.
DR   EMBL; AL133551; CAI16036.1; -; Genomic_DNA.
DR   EMBL; BC012499; AAH12499.1; ALT_INIT; mRNA.
DR   CCDS; CCDS7273.1; -. [Q96EB6-1]
DR   RefSeq; NP_001135970.1; NM_001142498.1.
DR   RefSeq; NP_001300978.1; NM_001314049.1.
DR   RefSeq; NP_036370.2; NM_012238.4. [Q96EB6-1]
DR   UniGene; Hs.369779; -.
DR   PDB; 4I5I; X-ray; 2.50 A; A/B=241-516.
DR   PDB; 4IF6; X-ray; 2.25 A; A=234-510, B=641-665.
DR   PDB; 4IG9; X-ray; 2.64 A; A/C/E/G=234-510, B/D/F/H=641-665.
DR   PDB; 4KXQ; X-ray; 1.85 A; A=234-510, B=641-663.
DR   PDB; 4ZZH; X-ray; 3.10 A; A=183-505.
DR   PDB; 4ZZI; X-ray; 2.73 A; A=183-505.
DR   PDB; 4ZZJ; X-ray; 2.74 A; A=183-505.
DR   PDB; 5BTR; X-ray; 3.20 A; A/B/C=143-665.
DR   PDBsum; 4I5I; -.
DR   PDBsum; 4IF6; -.
DR   PDBsum; 4IG9; -.
DR   PDBsum; 4KXQ; -.
DR   PDBsum; 4ZZH; -.
DR   PDBsum; 4ZZI; -.
DR   PDBsum; 4ZZJ; -.
DR   PDBsum; 5BTR; -.
DR   ProteinModelPortal; Q96EB6; -.
DR   SMR; Q96EB6; -.
DR   BioGrid; 116983; 242.
DR   DIP; DIP-29757N; -.
DR   IntAct; Q96EB6; 127.
DR   MINT; MINT-3052322; -.
DR   STRING; 9606.ENSP00000212015; -.
DR   BindingDB; Q96EB6; -.
DR   ChEMBL; CHEMBL4506; -.
DR   DrugBank; DB05073; SRT501.
DR   GuidetoPHARMACOLOGY; 2707; -.
DR   iPTMnet; Q96EB6; -.
DR   PhosphoSitePlus; Q96EB6; -.
DR   BioMuta; SIRT1; -.
DR   DMDM; 38258633; -.
DR   EPD; Q96EB6; -.
DR   MaxQB; Q96EB6; -.
DR   PaxDb; Q96EB6; -.
DR   PeptideAtlas; Q96EB6; -.
DR   PRIDE; Q96EB6; -.
DR   Ensembl; ENST00000212015; ENSP00000212015; ENSG00000096717. [Q96EB6-1]
DR   GeneID; 23411; -.
DR   KEGG; hsa:23411; -.
DR   UCSC; uc001jnd.3; human. [Q96EB6-1]
DR   CTD; 23411; -.
DR   DisGeNET; 23411; -.
DR   GeneCards; SIRT1; -.
DR   HGNC; HGNC:14929; SIRT1.
DR   HPA; CAB003855; -.
DR   HPA; HPA006295; -.
DR   HPA; HPA052351; -.
DR   MIM; 604479; gene.
DR   neXtProt; NX_Q96EB6; -.
DR   OpenTargets; ENSG00000096717; -.
DR   PharmGKB; PA37935; -.
DR   eggNOG; KOG2684; Eukaryota.
DR   eggNOG; COG0846; LUCA.
DR   GeneTree; ENSGT00870000136443; -.
DR   HOGENOM; HOG000038016; -.
DR   HOVERGEN; HBG054192; -.
DR   InParanoid; Q96EB6; -.
DR   KO; K11411; -.
DR   OMA; NYPSNKS; -.
DR   OrthoDB; EOG091G07CT; -.
DR   PhylomeDB; Q96EB6; -.
DR   TreeFam; TF105896; -.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-427359; SIRT1 negatively regulates rRNA Expression.
DR   SignaLink; Q96EB6; -.
DR   SIGNOR; Q96EB6; -.
DR   GeneWiki; Sirtuin_1; -.
DR   GenomeRNAi; 23411; -.
DR   PRO; PR:Q96EB6; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000096717; -.
DR   CleanEx; HS_SIRT1; -.
DR   ExpressionAtlas; Q96EB6; baseline and differential.
DR   Genevisible; Q96EB6; HS.
DR   GO; GO:0005677; C:chromatin silencing complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:UniProtKB.
DR   GO; GO:0005635; C:nuclear envelope; IDA:BHF-UCL.
DR   GO; GO:0005719; C:nuclear euchromatin; IDA:UniProtKB.
DR   GO; GO:0005720; C:nuclear heterochromatin; IDA:UniProtKB.
DR   GO; GO:0005637; C:nuclear inner membrane; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:BHF-UCL.
DR   GO; GO:0033553; C:rDNA heterochromatin; IDA:UniProtKB.
DR   GO; GO:0043425; F:bHLH transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0019213; F:deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IPI:UniProtKB.
DR   GO; GO:0004407; F:histone deacetylase activity; IDA:BHF-UCL.
DR   GO; GO:0043398; F:HLH domain binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:BHF-UCL.
DR   GO; GO:1990254; F:keratin filament binding; IPI:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0070403; F:NAD+ binding; IEA:InterPro.
DR   GO; GO:0017136; F:NAD-dependent histone deacetylase activity; IDA:BHF-UCL.
DR   GO; GO:0046969; F:NAD-dependent histone deacetylase activity (H3-K9 specific); ISS:UniProtKB.
DR   GO; GO:0034979; F:NAD-dependent protein deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0035257; F:nuclear hormone receptor binding; IPI:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:BHF-UCL.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0033558; F:protein deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:BHF-UCL.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding; IEA:Ensembl.
DR   GO; GO:0001525; P:angiogenesis; IDA:UniProtKB.
DR   GO; GO:0042595; P:behavioral response to starvation; IEA:Ensembl.
DR   GO; GO:0007569; P:cell aging; TAS:BHF-UCL.
DR   GO; GO:0001678; P:cellular glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:BHF-UCL.
DR   GO; GO:0071456; P:cellular response to hypoxia; IMP:UniProtKB.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; ISS:UniProtKB.
DR   GO; GO:0009267; P:cellular response to starvation; ISS:BHF-UCL.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB.
DR   GO; GO:0035356; P:cellular triglyceride homeostasis; ISS:UniProtKB.
DR   GO; GO:0042632; P:cholesterol homeostasis; ISS:UniProtKB.
DR   GO; GO:0006325; P:chromatin organization; IMP:UniProtKB.
DR   GO; GO:0006342; P:chromatin silencing; TAS:ProtInc.
DR   GO; GO:0000183; P:chromatin silencing at rDNA; IDA:UniProtKB.
DR   GO; GO:0032922; P:circadian regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; TAS:BHF-UCL.
DR   GO; GO:0006260; P:DNA replication; TAS:BHF-UCL.
DR   GO; GO:0000731; P:DNA synthesis involved in DNA repair; ISS:UniProtKB.
DR   GO; GO:0006343; P:establishment of chromatin silencing; IDA:BHF-UCL.
DR   GO; GO:0055089; P:fatty acid homeostasis; ISS:UniProtKB.
DR   GO; GO:0016575; P:histone deacetylation; IDA:UniProtKB.
DR   GO; GO:0070932; P:histone H3 deacetylation; IDA:BHF-UCL.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IMP:UniProtKB.
DR   GO; GO:0033210; P:leptin-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0010934; P:macrophage cytokine production; ISS:UniProtKB.
DR   GO; GO:0030225; P:macrophage differentiation; ISS:UniProtKB.
DR   GO; GO:0006344; P:maintenance of chromatin silencing; IMP:BHF-UCL.
DR   GO; GO:0006346; P:methylation-dependent chromatin silencing; TAS:UniProtKB.
DR   GO; GO:0007517; P:muscle organ development; IEA:UniProtKB-KW.
DR   GO; GO:0060766; P:negative regulation of androgen receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:2000480; P:negative regulation of cAMP-dependent protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IMP:BHF-UCL.
DR   GO; GO:2000655; P:negative regulation of cellular response to testosterone stimulus; IMP:BHF-UCL.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IDA:UniProtKB.
DR   GO; GO:0043518; P:negative regulation of DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:CACAO.
DR   GO; GO:0051097; P:negative regulation of helicase activity; IDA:UniProtKB.
DR   GO; GO:0071441; P:negative regulation of histone H3-K14 acetylation; IMP:CACAO.
DR   GO; GO:1900113; P:negative regulation of histone H3-K9 trimethylation; IEA:Ensembl.
DR   GO; GO:2000619; P:negative regulation of histone H4-K16 acetylation; IMP:CACAO.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:1902166; P:negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; ISS:BHF-UCL.
DR   GO; GO:1901215; P:negative regulation of neuron death; IEA:Ensembl.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:2000757; P:negative regulation of peptidyl-lysine acetylation; IDA:UniProtKB.
DR   GO; GO:0042326; P:negative regulation of phosphorylation; IMP:UniProtKB.
DR   GO; GO:0031393; P:negative regulation of prostaglandin biosynthetic process; ISS:UniProtKB.
DR   GO; GO:1901984; P:negative regulation of protein acetylation; IMP:CACAO.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0001542; P:ovulation from ovarian follicle; IEA:Ensembl.
DR   GO; GO:0018394; P:peptidyl-lysine acetylation; IMP:UniProtKB.
DR   GO; GO:0034983; P:peptidyl-lysine deacetylation; IDA:BHF-UCL.
DR   GO; GO:0002821; P:positive regulation of adaptive immune response; IDA:UniProtKB.
DR   GO; GO:1904179; P:positive regulation of adipose tissue development; ISS:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:2000481; P:positive regulation of cAMP-dependent protein kinase activity; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:2000774; P:positive regulation of cellular senescence; IDA:UniProtKB.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; ISS:UniProtKB.
DR   GO; GO:0031937; P:positive regulation of chromatin silencing; IMP:BHF-UCL.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045739; P:positive regulation of DNA repair; IMP:UniProtKB.
DR   GO; GO:1902237; P:positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:AgBase.
DR   GO; GO:0051574; P:positive regulation of histone H3-K9 methylation; IMP:UniProtKB.
DR   GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IDA:UniProtKB.
DR   GO; GO:2000111; P:positive regulation of macrophage apoptotic process; ISS:UniProtKB.
DR   GO; GO:0045348; P:positive regulation of MHC class II biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0051152; P:positive regulation of smooth muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0006476; P:protein deacetylation; IDA:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0000720; P:pyrimidine dimer repair by nucleotide-excision repair; IMP:UniProtKB.
DR   GO; GO:0070857; P:regulation of bile acid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0090335; P:regulation of brown fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:BHF-UCL.
DR   GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome.
DR   GO; GO:0032071; P:regulation of endodeoxyribonuclease activity; IMP:UniProtKB.
DR   GO; GO:0010906; P:regulation of glucose metabolic process; ISS:UniProtKB.
DR   GO; GO:0010883; P:regulation of lipid storage; ISS:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0035358; P:regulation of peroxisome proliferator activated receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0033158; P:regulation of protein import into nucleus, translocation; IMP:UniProtKB.
DR   GO; GO:0071900; P:regulation of protein serine/threonine kinase activity; IMP:AgBase.
DR   GO; GO:0034391; P:regulation of smooth muscle cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IDA:UniProtKB.
DR   GO; GO:0032868; P:response to insulin; ISS:UniProtKB.
DR   GO; GO:0044321; P:response to leptin; ISS:UniProtKB.
DR   GO; GO:0006979; P:response to oxidative stress; IDA:UniProtKB.
DR   GO; GO:0006364; P:rRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0000012; P:single strand break repair; IMP:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0090400; P:stress-induced premature senescence; IMP:CACAO.
DR   GO; GO:0006642; P:triglyceride mobilization; ISS:BHF-UCL.
DR   GO; GO:0070914; P:UV-damage excision repair; IMP:CACAO.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   GO; GO:0050872; P:white fat cell differentiation; ISS:BHF-UCL.
DR   Gene3D; 3.40.50.1220; -; 1.
DR   InterPro; IPR029035; DHS-like_NAD/FAD-binding_dom.
DR   InterPro; IPR003000; Sirtuin.
DR   InterPro; IPR026590; Ssirtuin_cat_dom.
DR   Pfam; PF02146; SIR2; 1.
DR   SUPFAM; SSF52467; SSF52467; 1.
DR   PROSITE; PS50305; SIRTUIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   Biological rhythms; Complete proteome; Cytoplasm;
KW   Developmental protein; Differentiation; Host-virus interaction;
KW   Hydrolase; Metal-binding; Methylation; Mitochondrion; Myogenesis; NAD;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   rRNA processing; S-nitrosylation; Transcription;
KW   Transcription regulation; Zinc.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    747       NAD-dependent protein deacetylase
FT                                sirtuin-1.
FT                                /FTId=PRO_0000110256.
FT   CHAIN         2    533       SirtT1 75 kDa fragment.
FT                                /FTId=PRO_0000415289.
FT   DOMAIN      244    498       Deacetylase sirtuin-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00236}.
FT   NP_BIND     261    280       NAD. {ECO:0000250}.
FT   NP_BIND     345    348       NAD. {ECO:0000250}.
FT   NP_BIND     440    442       NAD. {ECO:0000250}.
FT   NP_BIND     465    467       NAD. {ECO:0000250}.
FT   REGION        2    268       Interaction with HIST1H1E.
FT   REGION        2    139       Interaction with CLOCK.
FT                                {ECO:0000250|UniProtKB:Q923E4}.
FT   REGION      143    541       Interaction with CCAR2.
FT   REGION      256    259       Required for interaction with the
FT                                sumoylated form of CCAR2.
FT                                {ECO:0000269|PubMed:25406032}.
FT   REGION      538    540       Phosphorylated at one of three serine
FT                                residues.
FT   MOTIF        32     39       Nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       138    145       Nuclear export signal. {ECO:0000250}.
FT   MOTIF       223    230       Nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       425    431       Nuclear export signal. {ECO:0000250}.
FT   COMPBIAS     54     98       Ala-rich.
FT   COMPBIAS    122    127       Poly-Asp.
FT   COMPBIAS    128    134       Poly-Glu.
FT   ACT_SITE    363    363       Proton acceptor.
FT   METAL       371    371       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00236}.
FT   METAL       374    374       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00236}.
FT   METAL       395    395       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00236}.
FT   METAL       398    398       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00236}.
FT   BINDING     482    482       NAD; via amide nitrogen. {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES      14     14       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:19107194}.
FT   MOD_RES      26     26       Phosphoserine.
FT                                {ECO:0000269|PubMed:19107194}.
FT   MOD_RES      27     27       Phosphoserine; by MAPK8.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:18838864,
FT                                ECO:0000269|PubMed:19107194,
FT                                ECO:0000269|PubMed:20027304}.
FT   MOD_RES      47     47       Phosphoserine; by MAPK8.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:18838864,
FT                                ECO:0000269|PubMed:19107194,
FT                                ECO:0000269|PubMed:20027304,
FT                                ECO:0000269|PubMed:21471201}.
FT   MOD_RES     159    159       Phosphoserine.
FT                                {ECO:0000305|PubMed:19107194}.
FT   MOD_RES     162    162       Phosphoserine.
FT                                {ECO:0000305|PubMed:19107194}.
FT   MOD_RES     172    172       Phosphoserine.
FT                                {ECO:0000269|PubMed:19107194}.
FT   MOD_RES     173    173       Phosphoserine.
FT                                {ECO:0000269|PubMed:19107194}.
FT   MOD_RES     395    395       S-nitrosocysteine.
FT                                {ECO:0000250|UniProtKB:Q923E4}.
FT   MOD_RES     398    398       S-nitrosocysteine.
FT                                {ECO:0000250|UniProtKB:Q923E4}.
FT   MOD_RES     530    530       Phosphothreonine; by DYRK1A, DYRK3 and
FT                                MAPK8. {ECO:0000244|PubMed:19690332,
FT                                ECO:0000269|PubMed:19107194,
FT                                ECO:0000269|PubMed:20027304}.
FT   MOD_RES     535    535       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     544    544       Phosphothreonine.
FT                                {ECO:0000305|PubMed:19107194}.
FT   MOD_RES     545    545       Phosphoserine.
FT                                {ECO:0000305|PubMed:19107194}.
FT   MOD_RES     659    659       Phosphoserine; by CaMK2. {ECO:0000250}.
FT   MOD_RES     661    661       Phosphoserine; by CaMK2.
FT                                {ECO:0000305|PubMed:19236849}.
FT   MOD_RES     719    719       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:19107194}.
FT   MOD_RES     747    747       Phosphoserine.
FT                                {ECO:0000269|PubMed:19107194}.
FT   VAR_SEQ     454    639       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_042189.
FT   VARIANT       3      3       D -> E (in dbSNP:rs35671182).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025148.
FT   VARIANT     484    484       V -> D (in dbSNP:rs1063111).
FT                                /FTId=VAR_051976.
FT   MUTAGEN      27     27       S->A: Greatly diminishes phosphorylation
FT                                by MAPK8; when associated with A-47 and
FT                                A-530. {ECO:0000269|PubMed:20027304}.
FT   MUTAGEN      47     47       S->A: Blocks residue phosphorylation,
FT                                restores deacetylation activity and
FT                                inhibits DNA damage-induced apoptosis.
FT                                {ECO:0000269|PubMed:20027304,
FT                                ECO:0000269|PubMed:21471201}.
FT   MUTAGEN      47     47       S->A: Greatly diminishes phosphorylation
FT                                by MAPK8; when associated with A-27 and
FT                                A-530. {ECO:0000269|PubMed:20027304,
FT                                ECO:0000269|PubMed:21471201}.
FT   MUTAGEN     233    233       K->R: Impairs in vitro methylation by
FT                                SETD7; when associated with R-235, R-236
FT                                and R-238. {ECO:0000269|PubMed:21245319}.
FT   MUTAGEN     235    235       K->R: Impairs in vitro methylation by
FT                                SETD7; when associated with R-233, R-236
FT                                and R-238. {ECO:0000269|PubMed:21245319}.
FT   MUTAGEN     236    236       K->R: Impairs in vitro methylation by
FT                                SETD7; when associated with R-233, R-235
FT                                and R-238. {ECO:0000269|PubMed:21245319}.
FT   MUTAGEN     238    238       K->R: Impairs in vitro methylation by
FT                                SETD7; when associated with R-233, R-235a
FT                                and R-236. {ECO:0000269|PubMed:21245319}.
FT   MUTAGEN     256    257       II->KK: Loss of interaction with the
FT                                sumoylated form of CCAR2. No effect on
FT                                its deacetylation activity.
FT                                {ECO:0000269|PubMed:25406032}.
FT   MUTAGEN     363    363       H->Y: Loss of function. Reduces the
FT                                interaction with CCAR2 and APEX1.
FT                                Increases acetylation of APEX1.
FT                                {ECO:0000269|PubMed:11672523,
FT                                ECO:0000269|PubMed:12006491,
FT                                ECO:0000269|PubMed:12535671,
FT                                ECO:0000269|PubMed:17290224,
FT                                ECO:0000269|PubMed:18004385,
FT                                ECO:0000269|PubMed:18235501,
FT                                ECO:0000269|PubMed:18485871,
FT                                ECO:0000269|PubMed:19934257,
FT                                ECO:0000269|PubMed:25406032}.
FT   MUTAGEN     474    474       F->A: Abolishes phosphorylation at Ser-
FT                                47, restores deacetylation activity and
FT                                inhibits DNA damage-induced apoptosis.
FT                                {ECO:0000269|PubMed:21471201}.
FT   MUTAGEN     530    530       T->A: Greatly diminishes phosphorylation
FT                                by MAPK8; when associated with A-27 and
FT                                A-47. {ECO:0000269|PubMed:19107194,
FT                                ECO:0000269|PubMed:20027304}.
FT   MUTAGEN     530    530       T->A: Reduces in vitro phosphorylation by
FT                                CDK1. Impairs cell proliferation and cell
FT                                cycle progression; when associated with
FT                                A-540. {ECO:0000269|PubMed:19107194,
FT                                ECO:0000269|PubMed:20027304}.
FT   MUTAGEN     540    540       S->A: Reduces in vitro phosphorylation by
FT                                CDK1. Impairs cell proliferation and cell
FT                                cycle progression; when associated with
FT                                A-530. {ECO:0000269|PubMed:19107194}.
FT   MUTAGEN     659    659       S->A: Reduces in vitro phosphorylation by
FT                                CaMK2; when associated with S-661.
FT                                Greatly reduces in vivo phosphorylation;
FT                                when associated with A-661.
FT                                {ECO:0000269|PubMed:19236849}.
FT   MUTAGEN     661    661       S->A: Reduces in vitro phosphorylation by
FT                                CaMK2; when associated with S-659.
FT                                Greatly reduces in vivo phosphorylation;
FT                                when associated with A-659.
FT                                {ECO:0000269|PubMed:19236849}.
FT   MUTAGEN     684    684       S->A: No effect on phosphorylation (in
FT                                vitro and in vivo).
FT                                {ECO:0000269|PubMed:19236849}.
FT   CONFLICT    386    389       DIFN -> ALFS (in Ref. 5; AAH12499).
FT                                {ECO:0000305}.
FT   HELIX       184    194       {ECO:0000244|PDB:4ZZI}.
FT   HELIX       198    205       {ECO:0000244|PDB:4ZZI}.
FT   HELIX       217    228       {ECO:0000244|PDB:4ZZI}.
FT   HELIX       243    252       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      254    260       {ECO:0000244|PDB:4KXQ}.
FT   HELIX       262    268       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      273    275       {ECO:0000244|PDB:4KXQ}.
FT   TURN        276    278       {ECO:0000244|PDB:4IG9}.
FT   HELIX       279    286       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      290    292       {ECO:0000244|PDB:4KXQ}.
FT   HELIX       293    297       {ECO:0000244|PDB:4KXQ}.
FT   HELIX       299    304       {ECO:0000244|PDB:4KXQ}.
FT   HELIX       307    312       {ECO:0000244|PDB:4KXQ}.
FT   HELIX       313    316       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      318    320       {ECO:0000244|PDB:4I5I}.
FT   HELIX       325    335       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      339    344       {ECO:0000244|PDB:4KXQ}.
FT   HELIX       350    354       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      358    361       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      364    371       {ECO:0000244|PDB:4KXQ}.
FT   TURN        372    374       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      377    379       {ECO:0000244|PDB:4KXQ}.
FT   HELIX       380    382       {ECO:0000244|PDB:4KXQ}.
FT   HELIX       384    388       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      396    398       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      406    411       {ECO:0000244|PDB:4KXQ}.
FT   HELIX       420    429       {ECO:0000244|PDB:4KXQ}.
FT   TURN        430    432       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      435    440       {ECO:0000244|PDB:4KXQ}.
FT   HELIX       448    450       {ECO:0000244|PDB:4KXQ}.
FT   HELIX       451    454       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      461    467       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      475    480       {ECO:0000244|PDB:4KXQ}.
FT   HELIX       482    493       {ECO:0000244|PDB:4KXQ}.
FT   HELIX       495    500       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      506    510       {ECO:0000244|PDB:5BTR}.
FT   STRAND      643    645       {ECO:0000244|PDB:4KXQ}.
FT   TURN        646    648       {ECO:0000244|PDB:4KXQ}.
FT   STRAND      649    651       {ECO:0000244|PDB:4KXQ}.
FT   HELIX       656    658       {ECO:0000244|PDB:4KXQ}.
SQ   SEQUENCE   747 AA;  81681 MW;  2D3BEA6D73DA229F CRC64;
     MADEAALALQ PGGSPSAAGA DREAASSPAG EPLRKRPRRD GPGLERSPGE PGGAAPEREV
     PAAARGCPGA AAAALWREAE AEAAAAGGEQ EAQATAAAGE GDNGPGLQGP SREPPLADNL
     YDEDDDDEGE EEEEAAAAAI GYRDNLLFGD EIITNGFHSC ESDEEDRASH ASSSDWTPRP
     RIGPYTFVQQ HLMIGTDPRT ILKDLLPETI PPPELDDMTL WQIVINILSE PPKRKKRKDI
     NTIEDAVKLL QECKKIIVLT GAGVSVSCGI PDFRSRDGIY ARLAVDFPDL PDPQAMFDIE
     YFRKDPRPFF KFAKEIYPGQ FQPSLCHKFI ALSDKEGKLL RNYTQNIDTL EQVAGIQRII
     QCHGSFATAS CLICKYKVDC EAVRGDIFNQ VVPRCPRCPA DEPLAIMKPE IVFFGENLPE
     QFHRAMKYDK DEVDLLIVIG SSLKVRPVAL IPSSIPHEVP QILINREPLP HLHFDVELLG
     DCDVIINELC HRLGGEYAKL CCNPVKLSEI TEKPPRTQKE LAYLSELPPT PLHVSEDSSS
     PERTSPPDSS VIVTLLDQAA KSNDDLDVSE SKGCMEEKPQ EVQTSRNVES IAEQMENPDL
     KNVGSSTGEK NERTSVAGTV RKCWPNRVAK EQISRRLDGN QYLFLPPNRY IFHGAEVYSD
     SEDDVLSSSS CGSNSDSGTC QSPSLEEPME DESEIEEFYN GLEDEPDVPE RAGGAGFGTD
     GDDQEAINEA ISVKQEVTDM NYPSNKS
//
